WO2000057918A2 - Nouvelles formules comprenant des agents de regulation des lipides - Google Patents

Nouvelles formules comprenant des agents de regulation des lipides Download PDF

Info

Publication number
WO2000057918A2
WO2000057918A2 PCT/US2000/007459 US0007459W WO0057918A2 WO 2000057918 A2 WO2000057918 A2 WO 2000057918A2 US 0007459 W US0007459 W US 0007459W WO 0057918 A2 WO0057918 A2 WO 0057918A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
polyoxyethylene
caprylic
oil
lipid
Prior art date
Application number
PCT/US2000/007459
Other languages
English (en)
Other versions
WO2000057918A3 (fr
Inventor
Rong Liu (Ron)
Qinghai Pan
Pawan Hansrani
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP00919496A priority Critical patent/EP1165141A2/fr
Priority to AU40175/00A priority patent/AU4017500A/en
Priority to MXPA01009839A priority patent/MXPA01009839A/es
Priority to JP2000607667A priority patent/JP2002540174A/ja
Priority to CA002367995A priority patent/CA2367995A1/fr
Publication of WO2000057918A2 publication Critical patent/WO2000057918A2/fr
Publication of WO2000057918A3 publication Critical patent/WO2000057918A3/fr
Priority to HK02104718.1A priority patent/HK1044704A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to novel formulations comprising lipid-regulating agents.
  • 2- [4- (4-chlorobenzoyl) phenoxy] -2 -methyl -propanoic acid, 1-methylethylester, also known as fenofibrate, is representative of a broad class of compounds having pharmaceutical utility as lipid regulating agents. More specifically, this compound is part of a lipid-regulating agent class of compounds commonly known as fibrates, and is disclosed in U.S. Patent No. 4,058,552.
  • Fenofibrate has been prepared in several different formulations, c.f., U.S. Patent No. 4,800,079 and U.S. Patent No. 4,895,726.
  • U.S. Patent No. 4,895,726 discloses a co-micronized formulation of fenofibrate and a solid surfactant .
  • U.S. Patent No. 4,961,890 discloses a process for preparing a controlled release formulation containing fenofibrate in an intermediate layer in the form of crystalline microparticles included within pores of an inert matrix.
  • the formulation is prepared by a process involving the sequential steps of dampening said inert core with a solution based on said binder, then projecting said fenofibrate microparticles in a single layer onto said dampened core, and thereafter drying, before said solution based on said binder dissolves said fenofibrate microparticles, and repeating said three steps in sequence until said intermediate layer is formed.
  • EP0793958A2 discloses a process for producing a fenofibrate solid dosage form utilizing fenofibrate, a surface active agent and polyvinyl pyrrolidone in which the fenofibrate particles are mixed with a polyvinyl pyrrolidone solution. The thus obtained mixture is granulated with an aqueous solution of one or more surface active agents, and the granulate thus produced is dried.
  • PCT Publication No. WO 82/01649 discloses a fenofibrate formulation having granules that are comprised of a neutral core that is a mixture of saccharose and starch.
  • the neutral core is covered with a first layer of fenofibrate, admixed with an excipient and with a second microporous outer layer of an edible polymer.
  • U.S. Patent No. 5,645,856 describes the use of a carrier for hydrophobic drugs, including fenofibrate, and pharmaceutical compositions based thereon.
  • the carrier comprises a digestible oil and a pharmaceutically-acceptable surfactant component for dispersing the oil in vivo upon administration of the carrier, which comprises a hydrophilic surfactant, said surfactant component being such as not to substantially inhibit the in vivo lipolysis of the digestible oil.
  • Gemfibrozil is another member of the fibrate class of lipid-regulating agents.
  • U.S. Patent No. 4,927,639 discloses a disintegratable formulation of gemfibrozil providing both immediate and sustained release, comprising a tablet compressed from a mixture of a first and second granulation, and a disintegration excipient operable to effect partial or complete disintegration in the stomach.
  • the first granulation comprises finely divided particles of pure gemfibrozil granulated with at least one cellulose derivative
  • the second granulation comprises finely divided particles of pure gemfibrozil granulated with a pharmaceuitcally-acceptable water soluble or insoluble polymer which are then uniformly coated with a pharmaceuitcally-acceptable (meth) acylate copolymer prior to admixture with the first granulation.
  • the first and second granulations are present in the final composition in a ratio of from about 10:1 to about 1:10.
  • U.S. Patent 4,925,676 discloses a disintegratable gemfibrozil tablet providing both immediate and enteric release, which is compressed from a mixture of a first granulation of gemfibrozil with at least one acid- disintegratable binder, and a second granulation formed from the first granulation, but regranulated or coated with an alkali-disintegratable formulation of at least one substantially alkali-soluble and substantially acid- insoluble polymer.
  • statins Another class of lipid-regulating agents are commonly known as statins, of which pravastatin and atorvastatin are members.
  • U.S. Patents 5,030,447 and 5,180,589 describe stable pharmaceutical compositions, which when dispersed in water have a pH of at least 9, and include a medicament which is sensitive to a low pH environment, such as prevastatin, one or more fillers such as lactose and/or microcrystalline cellulose, one or more binders, such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder) , one or more disintegrating agents such as croscarmellose sodium, one or more lubricants such as magnesium stearate and one or more basifying agents such as magnesium oxide.
  • prevastatin one or more fillers such as lactose and/or microcrystalline cellulose
  • binders such as microcrystalline cellulose (dry binder) or polyvinylpyrrolidone (wet binder)
  • the present invention is directed to a formulation comprising a lipid-regulating agent dissolved in a mixture of an oil and one or more surfactants to form a concentrate.
  • This concentrate forms fine and stable emulsions upon gentle mixing with water or any aqueous solutions.
  • the emulsions result in an increase in drug solubility and oral bioavailability .
  • the formulation may be administered directly, diluted into an appropriate vehicle for administration, encapsulated into soft or hard gelatin capsules for administration, or administered by other means obvious to those skilled in the art.
  • Figure 1 is a graph showing the plasma concentration in fasted dogs of the formulation of Example 1 and a reference compound .
  • the bulk lipid-regulating agent may be prepared by any available method, as for example the compound fenofibrate may be prepared by the procedure disclosed in U.S. Patent No. 4,058,552, or the procedure disclosed in U.S. Patent No. 4,739,101, both herein incorporated by reference.
  • the solution comprising the lipid-regulating agent is prepared by premixing the oil and one and more surfactants, then adding the lipid-regulating agent to the premix and mixing the resulting mixture well until dissolved.
  • the delivery system of the present invention results in increased solubility, half-life and bioavailability of the lipid-regulating agent. It can be further diluted with additional liquids or it may be thickened and/or stabilized with various pharmaceutical excipients to vary its existing properties .
  • Suitable oils include, but are not limited to, any pharmaceutically acceptable oil, such as, for example, Myvacet 9-08 (distillated acetylated monoglycerides: manufacturer) , Myvacet 9-40 (distillated acetylated monoglycerides: manufacturer), Capmul PG-8 (propylene glycol and mono/di-caprylate; Abitec) , Arlamol E (polyoxypropylene (15) stearyl alcohol; ICI) , Captex 300 (glyceryl tricaprylate/caprate; Abitec), Labrafac Lipophile W 1349 (triglyceride of caprylic/capric acid; Gattefosse) , olive oil, Miglyol 812 ((caprylic/capric triglycerides ; HULS America), sesame oil, Novol (oleyl alcohol; Croda) .
  • Preferred oils include Myvacet 9-08, Myvacet 9-40, and Capmul PG-8 (
  • Suitable surfactants include any surfactant in which fenofibrate is highly soluble. Such surfactants will typically be those with HLB values ranging from about 1 to about 20. Representative surfactants include Labrafac
  • Lipophile WL 1349 (triglyceride of caprylic/capric acid; Gattefosse ), Lauroglycol FCC (propylene glycol laurate; Gattefosse) , Labrafil M 1944 CS (glyceryl and polyethylene glycol esters; Gattefosse), Span 80 (sorbitan monooleate; Sigma) , Capmul MCM (mono/diglycerides of caprylic/capric acid in glycerol; Abitec), Arlacel 83 (sorbitan sesquioleate; ICI) , Brij 93 (polyoxyethylene (2) oleyl ether; READ ICI) , Acconon E (polyoxypropylene 15 stearyl ether; Abitec) , Labrafil M 2125 CS (unsaturated polyglycolyzed glycerides; Gattefose) , Maisine 35-1
  • Gattefosse Labrafac CM 12 (polyglycolysed glycerides; Gattefosse) , Labrasol (saturated C8-C10 polyglycolysed glycerides; Gattefosse), Tween 80 (polyoxyethylene (20) sorbitan monooleate; Sigma), Tween 85 (polyoxyethylene (20) sorbitan trioleate; Sigma), Pluronic L43 (copolymers of propylene oxide and ethylene oxide; BASF) , Pluronic 17R4 (copolymers of propylene oxide and ethylene oxide; BASF) , Cremophor EL (polyoxyl 35 castor oil; BASF), Accomid PK (palm kernelamide DEA; Abitec) , Brij 30 (polyoxyethylene 4 lauryl ether; READ ICI) , Arlasolve 200 liquid
  • Preferred surfactants include Labrafac Lipophile WL 1349 (triglyceride of caprylic/capric acid; Gattefosse) , Labrofac CM 10 and CM 12 (polyglycolysed glycerides; Gattefosse) , Lauroglycol FCC (propylene glycol laurate; Gattefosse) , Peceol (glyceryl monooleate; Gattefosse) , Caprol 3G0 (triglyceryl monoleate; Abitec) , Capmul MCM (mono/diglycerides of caprylic/capric acid in glycerol; Abitec) , Labrasol (saturated C8-C10 polyglycolysed glycerides; Gattefosse) , Tween 80 (polyoxyethylene (20) sorbitan monooleate; Sigma), Pluronic L43 (copolymers of propylene oxide; BASF), Pluronic 17R4 (copolymers
  • antioxidants such as, for example, tocopherol, ascorbyl palmitate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, etc.
  • pH stabilizers such as, for example, citric acid, tartaric acid, fumaric acid, acetic acid, glycine, arginine, lysine, potassium hydrogen phosphate, etc.
  • thickeners/suspending agents such as, for example, hydrogenated vegetable oils, beeswax, colloidal silicon dioxide, gums, celluloses, silicates, bentonite, etc.
  • flavoring agents such as, for example, cherry, lemon, aniseed flavors, etc.
  • sweeteners such as, for example, aspartame, saccharin, cyclamates, etc.
  • co-solvents such as, for example, ethanol
  • the resulting liquid comprising the lipid-regulating agent may be dosed directly for oral administration, diluted into an appropriate vehicle for oral administration, filled into soft or hard shells or capsules for oral administration, or delivered by some other means obvious to those skilled in the art.
  • the said liquid can be used to improve the oral bioavailability and solubility of the said lipid-regulating agent.
  • Myvacet 9-08 (40.2 gm) was mixed with propylene glycol laurate (13.4 gm) . Fenofibrate (6.7 gm) was then added to the above mixture and mixed until completely dissolved. One drop of the solution was diluted with 10 ml of water and the droplet size was measured by laser light scattering as 2.95 (m. 670 mg of the mixture (containing 67 mg of fenofibrate) was added to each soft gelatin capsule.
  • Myvacet 9-08 (40.2 g) is mixed with propylene glycol laurate (13.4 g) .
  • Pravastatin 5.0 g is then added to the above mixture and mixed until well dissolved. Appropriate amount of solution may be filled into capsules to provide the desired dose.
  • the plasma concentrations of fenofibric acid were determined by HPLC . Concentrations were normalized to a 6.7 mg/kg dose in each dog.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une formule comprenant un agent de régulation des lipides, dissous dans un mélange d'huile et d'un ou plusieurs surnageants, de sorte qu'un concentré soit formé. Ledit concentré forme des émulsions fines et stables lorsqu'il est mélangé délicatement à de l'eau ou à une solution aqueuse, quelle qu'elle soit.
PCT/US2000/007459 1999-03-31 2000-03-21 Nouvelles formules comprenant des agents de regulation des lipides WO2000057918A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP00919496A EP1165141A2 (fr) 1999-03-31 2000-03-21 Nouvelles formules comprenant des agents de regulation des lipides
AU40175/00A AU4017500A (en) 1999-03-31 2000-03-21 Novel formulations comprising lipid-regulating agents
MXPA01009839A MXPA01009839A (es) 1999-03-31 2000-03-21 Nuevas formulaciones que comprenden agentes reguladores de lipido.
JP2000607667A JP2002540174A (ja) 1999-03-31 2000-03-21 脂質調節剤を含有する新規製剤
CA002367995A CA2367995A1 (fr) 1999-03-31 2000-03-21 Nouvelles formules comprenant des agents de regulation des lipides
HK02104718.1A HK1044704A1 (zh) 1999-03-31 2002-06-25 含有脂調節劑的新配方

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28335699A 1999-03-31 1999-03-31
US09/283,356 1999-03-31

Publications (2)

Publication Number Publication Date
WO2000057918A2 true WO2000057918A2 (fr) 2000-10-05
WO2000057918A3 WO2000057918A3 (fr) 2001-01-18

Family

ID=23085656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007459 WO2000057918A2 (fr) 1999-03-31 2000-03-21 Nouvelles formules comprenant des agents de regulation des lipides

Country Status (7)

Country Link
EP (1) EP1165141A2 (fr)
JP (1) JP2002540174A (fr)
AU (1) AU4017500A (fr)
CA (1) CA2367995A1 (fr)
HK (1) HK1044704A1 (fr)
MX (1) MXPA01009839A (fr)
WO (1) WO2000057918A2 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100394A1 (fr) * 2001-06-12 2002-12-19 Galephar M/F Composition pharmaceutique orale comprenant un derive de statine
JP2003342171A (ja) * 2002-05-23 2003-12-03 Usv Ltd ディスラノール投与のための組成物
WO2005034920A1 (fr) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S Forme de dose solide comprenant un fibrate
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2006045865A1 (fr) 2004-10-19 2006-05-04 Gp Pharm S.A. Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
US7927627B2 (en) 2002-05-24 2011-04-19 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7976869B2 (en) 2001-01-22 2011-07-12 Laboratoires Fournier S.A. Fenofibrate tablets
EP2400840A1 (fr) * 2009-02-24 2012-01-04 Madeira Therapeutics Formulations de statine liquide
WO2012171364A1 (fr) * 2011-06-13 2012-12-20 浙江爱生药业有限公司 Composition pharmaceutique soluble dans l'huile
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
WO2015185240A1 (fr) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
US9757390B2 (en) 2010-11-30 2017-09-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US9757389B2 (en) 2014-08-28 2017-09-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
US11052096B2 (en) 2009-01-08 2021-07-06 Lipocine Inc. Steroidal compositions
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11707467B2 (en) 2014-08-28 2023-07-25 Lipocine Inc. (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007006775A (es) * 2004-12-06 2008-02-25 Reliant Pharmaceuticals Inc Composiciones estables de fenofibrato con esteres de acido graso.
JP5186159B2 (ja) * 2006-08-31 2013-04-17 あすか製薬株式会社 フェノフィブラート含有組成物
JP2013047282A (ja) * 2006-08-31 2013-03-07 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0336298A1 (fr) * 1988-03-31 1989-10-11 E.R. Squibb & Sons, Inc. Compositions pharmaceutiques ayant une bonne stabilité
WO1995024893A1 (fr) * 1994-03-16 1995-09-21 R.P. Scherer Limited Systemes d'administration s'appliquant a des medicaments hydrophobes
WO1999012528A1 (fr) * 1997-09-11 1999-03-18 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee
WO1999029300A1 (fr) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Preparations autoemulsifiantes de fenofibrate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0336298A1 (fr) * 1988-03-31 1989-10-11 E.R. Squibb & Sons, Inc. Compositions pharmaceutiques ayant une bonne stabilité
WO1995024893A1 (fr) * 1994-03-16 1995-09-21 R.P. Scherer Limited Systemes d'administration s'appliquant a des medicaments hydrophobes
WO1999012528A1 (fr) * 1997-09-11 1999-03-18 Smb Technology Capsules semi-solides autoemulsionnables matricielles a action prolongee
WO1999029300A1 (fr) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Preparations autoemulsifiantes de fenofibrate

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7976869B2 (en) 2001-01-22 2011-07-12 Laboratoires Fournier S.A. Fenofibrate tablets
WO2002100394A1 (fr) * 2001-06-12 2002-12-19 Galephar M/F Composition pharmaceutique orale comprenant un derive de statine
JP2003342171A (ja) * 2002-05-23 2003-12-03 Usv Ltd ディスラノール投与のための組成物
US7927627B2 (en) 2002-05-24 2011-04-19 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7931917B2 (en) 2002-05-24 2011-04-26 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US9173847B2 (en) 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US8481078B2 (en) 2003-10-10 2013-07-09 Veloxis Pharmaceuticals A/S Solid dosage form comprising a fibrate
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US8124125B2 (en) 2003-10-10 2012-02-28 Veloxis Pharmaceuticals A/S Solid dosage form comprising a fibrate
WO2005034920A1 (fr) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S Forme de dose solide comprenant un fibrate
WO2006045865A1 (fr) 2004-10-19 2006-05-04 Gp Pharm S.A. Formulation pharmaceutique comprenant des microcapsules de statines en suspension dans des esters alkyliques d'acides gras polyinsatures (pufa)
US11052096B2 (en) 2009-01-08 2021-07-06 Lipocine Inc. Steroidal compositions
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2400840A4 (fr) * 2009-02-24 2012-08-01 Madeira Therapeutics Formulations de statine liquide
EP2400840A1 (fr) * 2009-02-24 2012-01-04 Madeira Therapeutics Formulations de statine liquide
US10799513B2 (en) 2010-11-30 2020-10-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US9757390B2 (en) 2010-11-30 2017-09-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US9943527B2 (en) 2010-11-30 2018-04-17 Lipocine Inc. High-strength testosterone undecanoate compositions
US9949985B2 (en) 2010-11-30 2018-04-24 Lipocine Inc. High-strength testosterone undecanoate compositions
US10226473B2 (en) 2010-11-30 2019-03-12 Lipocine Inc. High-strength testosterone undecanoate compositions
US10973833B2 (en) 2010-11-30 2021-04-13 Lipocine Inc. High-strength testosterone undecanoate compositions
US10716794B2 (en) 2010-11-30 2020-07-21 Lipocine Inc. High-strength testosterone undecanoate compositions
US10561615B2 (en) 2010-12-10 2020-02-18 Lipocine Inc. Testosterone undecanoate compositions
WO2012171364A1 (fr) * 2011-06-13 2012-12-20 浙江爱生药业有限公司 Composition pharmaceutique soluble dans l'huile
WO2015185240A1 (fr) 2014-06-04 2015-12-10 Sigma-Tau Industrire Farmaceutiche Riunite S.P.A. Compositions contenant de la simvastatine dans des acides gras polyinsaturés oméga-3
US9757389B2 (en) 2014-08-28 2017-09-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US11298365B2 (en) 2014-08-28 2022-04-12 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US11707467B2 (en) 2014-08-28 2023-07-25 Lipocine Inc. (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use
US11872235B1 (en) 2014-08-28 2024-01-16 Lipocine Inc. Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy

Also Published As

Publication number Publication date
JP2002540174A (ja) 2002-11-26
CA2367995A1 (fr) 2000-10-05
HK1044704A1 (zh) 2002-11-01
AU4017500A (en) 2000-10-16
EP1165141A2 (fr) 2002-01-02
WO2000057918A3 (fr) 2001-01-18
MXPA01009839A (es) 2002-06-21

Similar Documents

Publication Publication Date Title
US6372251B2 (en) Formulations comprising lipid-regulating agents
EP1165141A2 (fr) Nouvelles formules comprenant des agents de regulation des lipides
WO2000057859A1 (fr) Preparations contenant des agents regulateurs de lipides
US6465011B2 (en) Formulations comprising lipid-regulating agents
WO2000037057A2 (fr) Formulations comprenant des liporegulateurs
RU2211047C2 (ru) Желатиновые капсулы с твердым покрытием, включающие фармацевтические композиции, практически не содержащие масел
US20040052824A1 (en) Micellar colloidal pharmaceutical composition containing a lipophilic active principle
US6838091B2 (en) Formulations comprising lipid-regulating agents
US6719999B2 (en) Formulations comprising lipid-regulating agents
WO1999029300A1 (fr) Preparations autoemulsifiantes de fenofibrate
ES2239605T3 (es) Composiciones de ciclosporina substancialmente libres de aceites.
NZ552390A (en) Novel fenofibrate formulations and related methods of treatment
SK286967B6 (sk) Spontánne dispergovateľná farmaceutická kompozícia N-benzoylstaurosporínu
US6814977B1 (en) Formulations comprising lipid-regulating agents
US20020040046A1 (en) Novel formulations comprising lipid-regulating agents
SK7342000A3 (en) Formulations comprising dissolved paroxetine
US7014864B1 (en) Formulations comprising lipid-regulating agents
EP1183017A1 (fr) Formulations comprenant des agents regulateurs des lipides
TW200409644A (en) Improved carrier system for cyclosporin pharmaceutical compositions
MXPA06005247A (es) Composicion farmaceutica destinada a la administracion oral de un derivado de pirazol-3-carboxamida

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367995

Country of ref document: CA

Ref country code: CA

Ref document number: 2367995

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 607667

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/009839

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2000919496

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000919496

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000919496

Country of ref document: EP